SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of segment revenues and profit

Segment revenues and profits were as follows:

	Three Months Ended March 31,
(in millions)	2024		2023
Revenues:
Salix	$	499	$	496
International	265		247
Solta Medical	88		73
Diversified	202		197
Bausch + Lomb	1,099		931
	$	2,153	$	1,944
Segment profits:
Salix	$	329	$	314
International	87		77
Solta Medical	40		36
Diversified	114		107
Bausch + Lomb	242		211
	812		745
Corporate	(244)		(251)
Amortization of intangible assets	(274)		(273)
Asset impairments	(1)		(13)
Restructuring, integration and separation costs	(12)		(10)
Other expense, net	—		(23)
Operating income	281		175
Interest income	9		6
Interest expense	(355)		(307)
Gain on extinguishment of debt	11		—
Foreign exchange and other	(15)		(10)
Loss before income taxes	$	(69)	$	(136)

Schedule of revenues by segment and product category

Revenues by segment and product category were as follows:

(in millions)	Salix		International		Solta Medical		Diversified		Bausch + Lomb		Total
	Three Months Ended March 31, 2024
Pharmaceuticals	$	499	$	56	$	—	$	171	$	209	$	935
Devices	—		—		88		—		424		512
OTC	—		41		—		1		395		437
Branded and Other Generics	—		153		—		26		66		245
Other revenues	—		15		—		4		5		24
	$	499	$	265	$	88	$	202	$	1,099	$	2,153
	Three Months Ended March 31, 2023
Pharmaceuticals	$	496	$	57	$	—	$	162	$	108	$	823
Devices	—		—		73		—		406		479
OTC	—		39		—		2		353		394
Branded and Other Generics	—		138		—		27		61		226
Other revenues	—		13		—		6		3		22
	$	496	$	247	$	73	$	197	$	931	$	1,944

Schedule of revenue attributed to a geographic region

Revenues are attributed to a geographic region based on the location of the customer and were as follows:

	Three Months Ended March 31,
(in millions)	2024		2023
U.S. and Puerto Rico	$	1,254	$	1,111
China	97		88
Canada	90		84
Poland	86		75
Mexico	76		69
France	61		57
Germany	44		43
Japan	43		50
Russia	36		34
United Kingdom	33		30
South Korea	30		22
Italy	24		21
Spain	23		22
Other	256		238
	$	2,153	$	1,944

Schedule of customers that accounted for 10% or more of total revenue

Customers that accounted for 10% or more of total revenues were as follows:

	Three Months Ended March 31,
	2024	2023
Cencora Inc.	18%	19%
McKesson Corporation (including McKesson Specialty)	16%	14%
Cardinal Health, Inc.	14%	13%